PMDA drug package insert
本草 かぜ内服液小児用-ＳＸ
PMDA OTC drug · 本草製薬（株） · package insert Apr 1, 2023
Key facts
| Brand names | 本草 かぜ内服液小児用-ＳＸ |
|---|---|
| Companies | 製造販売元／会社名：大生堂薬品工業株式会社,販売会社／本草製薬（株） |
| Product type | OTC drug |
| OTC risk class | 第「２」類医薬品 |
| OTC dosage form | 液剤 |
| OTC effect category | かぜ薬（内用） |
| Package insert date | Apr 1, 2023 |
| PMDA document key | 400068_K2002000007 |
| PMDA company code | 400068 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- 1–9 Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: